[1]王一苇,李明强,范为民,等.国医大师李济仁治疗肿瘤术后虚劳病的药物配伍与剂量值数据挖掘[J].西部中医药,2021,34(01):59-65.[doi:10.12174/j.issn.2096-9600.2021.01.17]
 WANG Yiwei,LI Mingqiang,FAN Weimin,et al.Study on National TCM Master Li Jiren’s Drug Compatibility and Dosage Rules of Treating Consumptive Disease after Tumor Operation Based on Data Mining[J].Western Journal of Traditional Chinese Medicine,2021,34(01):59-65.[doi:10.12174/j.issn.2096-9600.2021.01.17]
点击复制

国医大师李济仁治疗肿瘤术后虚劳病的药物配伍与剂量值数据挖掘
分享到:

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
34
期数:
2021年01期
页码:
59-65
栏目:
出版日期:
2021-01-15

文章信息/Info

Title:
Study on National TCM Master Li Jiren’s Drug Compatibility and Dosage Rules of Treating Consumptive Disease after Tumor Operation Based on Data Mining
作者:
王一苇1, 李明强2, 范为民2, 纪超凡2, 李艳2
1.皖南医学院基础医学院,安徽 芜湖 241002
2.皖南医学院附属弋矶山医院中医科/国医大师工作室
Author(s):
WANG Yiwei1, LI Mingqiang2, FAN Weimin2, JI Chaofan2, LI Yan2
1.School of Basic Medical Sciences, Wannan Medical College, Wuhu 241002, China
2.TCM Department, The First Affiliated Hospital of Wannan Medical College/Studio of National TCM Master
关键词:
虚劳病肿瘤术后中药剂量数据挖掘中、老年人李济仁
Keywords:
consumptive diseaseafter the operation of tumorherbal dosedata miningmiddle aged and elderly patients
分类号:
R273
DOI:
10.12174/j.issn.2096-9600.2021.01.17
摘要:
目的从药物配伍与剂量值的角度探讨国医大师李济仁治疗中老年患者肿瘤术后虚劳病的用药特点。 方法对李济仁教授治疗中老年肿瘤术后虚劳病患者的处方进行描述性分析、关联分析和聚类分析。 结果550首处方中共用药物310味,相应剂量值823种;频率>10%的40味中药中,有54种频率>5%的高频剂量值;频次前5位的药物为黄芪(480)、半枝莲(383)、半边莲(372)、白术(288)、全蝎(273)。关联规则提示,组方以黄芪为核心,支持度≥0.60、置信度≥0.96的剂量值组合包括“白术15 g,半枝莲15 g→半边莲15 g”“黄芪35 g,半边莲15 g→半枝莲15 g”;具有高相关度的药物剂量值包括黄芪35 g、白术15 g、白花蛇舌草30 g、半枝莲15 g、半边莲15 g等。系统聚类法分别形成4至5类药物与剂量值的聚类方。超过半数的药物剂量达到或超过了《中华人民共和国药典》记载的最大用量。 结论李济仁教授治疗中老年患者肿瘤术后虚劳病常以35~50 g黄芪配伍白术15 g、白花蛇舌草30 g、猫爪草30 g、半枝莲15 g、半边莲15 g,用量较《中华人民共和国药典》记载偏大,但临床疗效较好。
Abstract:
ObjectiveTo explore national TCM master Li Jiren’s characteristics of medication for consumptive disease in senile patients after tumor operation from drug compatibility and dosage vaules. MethodsDescription analysis, association analysis and cluster analysis were conducted on professor Li Jiren’s prescriptions for consumptive disease in senile patients after tumor operation . ResultsAmong 550 prescriptions, 310 herbs were used, 823 corresponding dosages, among forty herbs with the frequency greater than 10%, there were 54 high frequency dosages with the frequency higher than 5%; top five herbs in frequency were Huangqi (Astragali Radix, 480), Banzhilian (Scutellariabarbata.Don, 383), Banbianlian (Lobeliae Chinensis Herba, 372), Baizhu (Atractylodes Macrocephala, 288) and Quanxie (Scorpio, 273). Association rules suggested that the core of the prescription was Huangqi, dosage value combination with support≥0.60, confidence≥0.96 were “Baizhu 15 g, Banzhilian 15 g→Banbianlian 15 g” and “Huangqi 35 g, Banbianlian 15 g→Banzhilian 15 g”; the dosage value with high correlation contained Huangqi 35 g, Baizhu 15 g, Baihua Sheshecao (Spreading Hedyotis Herba)30 g, Banzhilian 15 g, Banbianlian 15 g and others. Four to five kinds of cluster square of drug and dosage values were formed by cluster analysis. More than half of the drug dose reached or exceeded the maximum dosage recorded in Pharmacopoeia. ConclusionProfessor Li Jiren could obtain notable clinical effects in treating consumptive disease after the operation of tumor through applying Huangqi, between 35 and 50 g, compatible with Baizhu, 15 g, Baihua Sheshecao, 30 g, Maozhuacao, 30 g, Banzhilian 15 g and Banbianlian, 15 g, with the doses greater than these of Pharmacopoeia.

相似文献/References:

[1]刘馨遥,田云梦,梁永瑞,等.李应存教授运用调肝补肾法论治肝肾型虚劳经验[J].西部中医药,2024,37(05):52.[doi:10.12174/j.issn.2096-9600.2024.05.08]
 LIU Xinyao,TIAN Yunmeng,LIANG Yongrui,et al.Professor Li Yingcun's Experience in Treating Chronic Consumption of Liver and Kidney Pattern by Regulating-liver Tonifying-kidney Method[J].Western Journal of Traditional Chinese Medicine,2024,37(01):52.[doi:10.12174/j.issn.2096-9600.2024.05.08]

备注/Memo

备注/Memo:
王一苇(1994—),男,硕士学位。研究方向:风湿病的中西医结合诊治。国家中医药管理局重点学科中医痹病学建设项目(国中医药人教发〔2012〕32号);安徽省科技计划项目(11010402173);安徽省卫生计生委中医药科研项目(2014zy27)。
更新日期/Last Update: 2021-01-15